What is ALAONCO 1.5g
ALAONCO is a prescription‑only (POM) medicinal product comprising **1.5 g of 5‑Aminolevulinic Acid Hydrochloride (5‑ALA HCl)** in granule form, produced by SBI Neopharma. Each single‑use sachet is designed for oral reconstitution prior to administration.
- Therapeutic use: Employed as a **photosensitising agent** in **photodynamic therapy (PDT)** or fluorescence-guided procedures for dermatological and oncological indications :contentReference[oaicite:1]{index=1}.
- Primary indications include: Treatment of minimally to moderately thick actinic keratoses on the face or scalp under blue light PDT; and visualization of malignant tissues—e.g., in bladder cancer or gliomas—via fluorescence-guided resection :contentReference[oaicite:2]{index=2}.
- Pharmacological class: A porphyrin precursor that increases **protoporphyrin IX (PpIX)** levels in targeted tissues, acting as a prodrug in PDT :contentReference[oaicite:3]{index=3}.
- Clinical approval: Approved for dermatologic PDT in the UAE and similar formulations (e.g., Gliolan, Alaglio) are approved in the EU and Japan for tumor visualization during surgery :contentReference[oaicite:4]{index=4}.
- Dosage form benefits: Single-dose granule sachet ensures consistent dosing, precise administration, and aligns with scheduled treatment protocols.
How to use ALAONCO 1.5g
Proper use of ALAONCO optimizes photosensitisation and minimizes adverse effects. Below is a general, structured protocol:
- Reconstitution: Dissolve the entire 1.5 g sachet in a glass of water (typically ~100 mL) according to local product guidelines.
- Timing before procedure:
- For dermatologic PDT: Administer 14–18 hours before blue light exposure (per local protocol).
- For tumor visualization (e.g., bladder cancer or glioma): Administer typically **2–8 hours** before procedure :contentReference[oaicite:5]{index=5}.
- With or Without Food: Can be taken irrespective of meals; water-based hydration aids absorption.
- Pre-treatment precautions: Shield eyes and skin from strong light sources post-dose; avoid bright indoor and outdoor light for up to 24 hours :contentReference[oaicite:6]{index=6}.
- Hydration: Encourage fluid intake to facilitate renal excretion of excess ALA or PpIX.
- Compliance: Single-dose regimen aids adherence and avoids dosing errors relative to multi-step treatments.
- Missed dose: If planned procedure is delayed beyond 12 hours, administer a fresh dose **2–4 hours** before rescheduled time; do *not* redose beyond that window :contentReference[oaicite:7]{index=7}.
Mode of Action ALAONCO 1.5g
ALAONCO acts by selectively localizing phototoxic protoporphyrin IX (PpIX) in diseased tissues:
- 5‑ALA → PpIX biosynthesis: Orally administered ALA is metabolized through the **heme biosynthesis pathway**, where it is converted to PpIX in epithelial or neoplastic cells :contentReference[oaicite:8]{index=8}.
- PpIX accumulation: Cancerous or dysplastic cells have reduced ferrochelatase activity, leading to **preferential accumulation of PpIX** compared to normal tissue :contentReference[oaicite:9]{index=9}.
- Light absorption: PpIX absorbs specific wavelengths (e.g., 410 nm violet-blue, 630 nm red), entering an excited state.
- Reactive oxygen generation: Excited PpIX transfers energy to oxygen, producing **singlet oxygen** and ROS that destroy cellular components and vasculature, inducing targeted cell death :contentReference[oaicite:10]{index=10}.
- Dual clinical effect:
- In PDT: Enables selective cytotoxicity of superficial lesions (e.g., actinic keratosis).
- In fluorescence-guided surgery: PpIX fluorescence delineates tumor margins for enhanced surgical resection accuracy :contentReference[oaicite:11]{index=11}.
- Endogenous metabolic pathway: Aligns with normal heme synthesis, allowing rapid clearance and reduced systemic toxicity :contentReference[oaicite:12]{index=12}.
ALAONCO 1.5g Interactions ALAONCO 1.5g
Being a metabolic precursor rather than a classic drug, ALAONCO’s interaction profile is distinct:
- Photosensitizing agents: Co-administration with other photosensitisers—such as tetracyclines, sulfonamides, fluoroquinolones, or St. John’s wort—can amplify photosensitivity. Avoid for at least **2 weeks** post-treatment :contentReference[oaicite:13]{index=13}.
- Hepatotoxic medications: Concurrent hepatotoxic drugs during the 24‑hour post-dose window may potentiate liver injury risk; monitoring is advised :contentReference[oaicite:14]{index=14}.
- Porphyria concern: Contraindicated with porphyrin pathway disorders; may provoke acute attacks :contentReference[oaicite:15]{index=15}.
- Photosensitizing supplements: Avoid co-use with herbal extracts like hypericin that may increase photoreactivity :contentReference[oaicite:16]{index=16}.
- Light therapy devices: Strict adherence to timing protocols is essential; improper light timing may reduce efficacy or cause unintended tissue damage.
Dosage of ALAONCO 1.5g
Dosage depends on indication, patient weight, and timing requirements:
- Dermatologic PDT: A single **1.5 g sachet**, administered ~14–18 hours before blue light exposure, per approved local protocols :contentReference[oaicite:17]{index=17}.
- Bladder cancer visualization: Japan’s Alaglio regimen: **20 mg/kg orally (approx. 1.5 g)**, 2–8 hours prior to cystoscopy or TURBT :contentReference[oaicite:18]{index=18}.
- Glioma fluorescence (Gliolan): ~20 mg/kg administered 2–4 hours before induction of anesthesia :contentReference[oaicite:19]{index=19}.
- Pediatric use: Not established; current use is limited to adults :contentReference[oaicite:20]{index=20}.
- Renal/hepatic impairment: No formal dose adjustments established; use caution and monitor patients closely :contentReference[oaicite:21]{index=21}.
- Missed or delayed procedure: If >12 hours elapse, repeat dose 2–4 hours before rescheduled exposure; do **not** double the dose :contentReference[oaicite:22]{index=22}.
Possible side effects of ALAONCO 1.5g
Adverse effects primarily arise from phototoxicity and metabolic changes in porphyrin pathways:
- Photosensitivity reactions (very common): Burning or stinging sensations on exposed skin or eyes upon light exposure—avoid strong light for 24 hours post-dose :contentReference[oaicite:23]{index=23}.
- Gastrointestinal discomfort: Nausea, abdominal pain, diarrhea—generally mild, managed symptomatically.
- Headache/dizziness: Frequently reported; ensure hydration and rest.
- Hypotension: Transient drops in blood pressure may occur—monitor in patients with cardiovascular conditions :contentReference[oaicite:24]{index=24}.
- Allergic reactions: Rare rash or urticaria; treat as needed and consider discontinuation if severe.
- Liver enzyme elevations: Mild transaminase rises possible; monitor during the peri-dosing period.
- Serious reactions: Rare photosensitivity burns or ocular injury from premature light exposure—ensure patient education and adherence to light avoidance protocol.
ALAONCO 1.5g Contraindications ALAONCO 1.5g
Contraindications include:
- Hypersensitivity: To ALA, PpIX precursors, porphyrins, or excipients.
- Porphyria (acute or chronic): Contraindicated due to risk of triggering porphyrin pathway crises :contentReference[oaicite:25]{index=25}.
- Pediatric use (<18 years): Not established for children and adolescents :contentReference[oaicite:26]{index=26}.
- Pregnancy: Not recommended—animal studies show embryo/fetal risk under light exposure; human safety unknown :contentReference[oaicite:27]{index=27}.
- Lactation: Unknown transfer of ALA/PpIX in milk—avoid breastfeeding for 24 hours post-dose :contentReference[oaicite:28]{index=28}.
- Severe renal or hepatic impairment: Caution advised due to unknown pharmacokinetics; use only if benefits outweigh risks :contentReference[oaicite:29]{index=29}.
Storage of ALAONCO 1.5g
- Temperature: Store between 2–25 °C (36–77 °F); avoid excessive heat or freezing.
- Humidity and light protection: Keep sachets in original sealed packaging to protect from moisture and light.
- Expiry: Use before the printed expiration date; expired product may lose efficacy or stability.
- Post-opening: Open only immediately before reconstitution; discard unused granules.
- Children safety: Store out of reach to prevent accidental ingestion.
- Disposal: Follow local drug disposal regulations; do not dispose via sink or toilet to avoid environmental contamination.
ALAONCO 1.5g features an exceptional active ingredient renowned for its potent effects, comprising 5-Aminolevulinic Acid Hydrochloride. This powerful formulation provides a superior solution for addressing diverse health concerns. With 1.5g/Sachet concentration and an easily manageable Granules, it remains a preferred option for countless individuals seeking effective treatment.
Introduction
All you need to know about ALAONCO 1.5g .
Welcome to Dwaey, specifically on ALAONCO 1.5g page.
This medicine contains an important and useful components, as it consists of 5-Aminolevulinic Acid Hydrochloride.
ALAONCO 1.5g is available in the market in concentration 1.5g/Sachet and in the form of Granules.
SBI NEOPHARMA is the producer of ALAONCO 1.5g and it is imported from UAE,
The most popular alternatives of ALAONCO 1.5g are listed downward .
-
Active Substance
5-Aminolevulinic Acid Hydrochloride
-
Size
-
Indications
- No indications available.
-
Type
-
Company
Frequently Asked Questions
ALAONCO 1.5g should be stored according to the instructions provided by SBI NEOPHARMA.
In general, it is recommended to store ALAONCO 1.5g in a cool, dry place, away from direct sunlight
and out of the reach of children.
The duration of treatment with ALAONCO 1.5g may vary depending on the condition being treated
and the guidance of your healthcare provider. It is important to follow the prescribed treatment
plan and continue taking ALAONCO 1.5g for the recommended duration, even if your symptoms improve.
If you have any concerns or questions about the duration of treatment, consult your healthcare provider.
It is important to check with your healthcare provider or read the medication label for specific
instructions regarding alcohol consumption while taking ALAONCO 1.5g. Some medications, including
ALAONCO 1.5g, may have interactions with alcohol that can reduce effectiveness, increase side
effects, or pose other risks to your health. It is best to follow the guidance provided by your
healthcare professional.
If you miss a dose of ALAONCO 1.5g, take it as soon as you remember. However, if it is close
to the time for your next scheduled dose, skip the missed dose and continue with your regular dosing
schedule. Do not take a double dose to make up for a missed one unless advised by your healthcare provider.
No, do not stop taking ALAONCO 1.5g without consulting your healthcare provider, even if your
symptoms improve. It is important to complete the full course of treatment as prescribed. Stopping
the medication prematurely may lead to a relapse or incomplete resolution of the condition. If you
have concerns about the duration of treatment, consult your healthcare provider for guidance.
It is important to consult your healthcare provider before taking ALAONCO 1.5g if you are
pregnant or breastfeeding. They will be able to assess the potential risks and benefits based on your
specific situation. Please note that the safety and suitability of ALAONCO 1.5g during pregnancy
or breastfeeding may depend on the active substance [Active Substance], concentration 1.5g/Sachet,
and the specific recommendations of SBI NEOPHARMA.
The effects of ALAONCO 1.5g on your ability to drive or operate machinery can vary depending on
the active substance [Active Substance], concentration 1.5g/Sachet, and individual factors.
Some medications may cause drowsiness, dizziness, or other side effects that can impair your judgment
or coordination. It is important to read the medication label or consult your healthcare provider to
understand any potential effects on your ability to perform tasks that require alertness.
The instructions for taking ALAONCO 1.5g with or without food may vary depending on the medication
and the recommendations of SBI NEOPHARMA. Some medications may be more effective when taken with
food to enhance absorption or reduce stomach irritation, while others may need to be taken on an empty
stomach for optimal absorption. Read the medication label or consult your healthcare provider for specific instructions.
The use of ALAONCO 1.5g in children or elderly individuals may depend on various factors, including
the specific medication, type Granules, and the recommendations of SBI NEOPHARMA. Some
medications may have specific dosing instructions or precautions for these age groups. Consult your
healthcare provider or read the medication label for information regarding the safe and appropriate use
of ALAONCO 1.5g in children or elderly individuals.
Dwaey
All medical information published on the Dwaey website aims to increase medical awareness and health education among users. However, it is not a substitute for professional medical advice. Always consult with a specialist doctor. We strongly advise against using any information or medicine found on the site without referring to your healthcare provider.
Related Products
0 Comments